Phase II randomized 2: 1 study to compare the efficacy and safety of treatment with standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in newly diagnosed adult AML patients with the non-mutated FLT3 gene
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: PETHEMA FOUNDATION
- Phase: II
- Execution start: 18/10/2019
- End of execution: 30/12/2024
- PI: ANTONIO ROMERO AGUILAR